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 CHAPTER I 
 
INTRODUCTION 
 
 Pancreatic islet transplantation shows potential for the treatment of type 1 diabetes 
mellitus.  The recent success of transplants using the Edmonton Protocol indicates that islet 
transplantation is indeed a feasible treatment for type 1 diabetes [1].  Advances in islet isolation 
and immunosuppression have greatly improved the success of these transplants.  However, the 
number of islets needed to overcome diabetes presents a major obstacle precluding islet 
transplantation from being adopted as a routine treatment.  Most patients require islets isolated 
from at least two pancreata.  The supply of islets from organ donors falls well short of the 
amount needed to treat the estimated 17 million type 1 diabetics in the United States [2].  The 
survival rate of transplanted islets is unknown; it is thought that many islets die post 
transplantation without engrafting.  Thus a significant amount of research is focused on 
preserving or increasing islet mass post transplantation.  However, there is currently no suitable 
method of non-invasively measuring islet mass.  Islet mass is commonly estimated from insulin 
secretion following glucose tolerance testing.  However, this method assesses islet function, 
which does not necessarily correlate with islet mass.  Morphometric analysis of histological 
sections of islet grafts can be used to measure islet mass, but requires removal of the organ 
containing the islets, preventing any sequential studies.  Additionally, this morphometric analysis 
is difficult to perform when islets are scattered, as they are when embolizing in the liver.   
This study seeks to develop in vivo bioluminescence imaging (BLI) as a method to 
quantify the number of islets surviving post transplantation.  The firefly luciferase reporter gene 
was inserted into the islets by means of an adenovirus to provide a means of tracking islets by 
light emission. These pancreatic islets were then transplanted beneath the renal capsule or 
infused into the portal vein of NOD-SCID mice.  The light emitted from these bioluminescent 
islets was imaged and quantified using an ultra-sensitive CCD camera.  As the mice bearing the 
islet transplant could be imaged repeatedly, bioluminescence (and thus islet mass) could be 
tracked temporally.   
In order to validate the method of bioluminescence imaging for assessing transplanted 
islets mass, the factors that influence light emission were examined.  The amount of light 
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 reaching the camera is determined by the optical properties of the tissue through which the light 
must pass and the geometry of the sample relative to the imaging system.  Constant emission, 
isotropic light emitting beads with spectral emission similar to the luciferase reaction were 
implanted at the renal capsule or within the liver of NOD-SCID mice.  These beads provided a 
constant source of luminescence from a location used for islet transplants.  These bead-implanted 
mice were used for investigation of the tissue optics governing light transmission from the islet 
grafts to the camera aperture.   The effects of wound healing, mouse positioning, and light 
attenuation by tissues overlying the islet grafts were determined by imaging these bead-
implanted mice.   
 
History of Islet Transplantation 
While the current success of islet transplantation has only recently established it as an 
effective clinical treatment for type 1 diabetes, the motivation behind islet transplantation is over 
a century old.  The link between diabetes and the pancreas was first discovered in 1889 in studies 
of a pancreatectomized dog which developed acute hyperglycemia and glucosuria [3].  Three 
years later Minkowski successfully transplanted autologous sections of the pancreas into a 
pancreatectomized dog [4].  The first clinical implementation of pancreas transplantation was 
performed in 1894 on a patient with diabetes ketoacidosis.  Three pieces of a sheep pancreas 
were transplanted subcutaneously in a 13-year-old recipient.   The patient showed temporary 
improvement in glucosuria before his death three days later from autoimmune rejection of the 
xenograft [5].  The first successful reversal of hyperglycemia was accomplished by Banting, et 
al, in 1922 by treatment with bovine pancreatic extract [6].  Purified insulin production 
commenced the following year.  Insulin therapy became the definitive treatment for diabetics.   
 Despite the success of insulin injections in overcoming hyperglycemia, they fail to 
prevent a number of the chronic ailments associated with diabetes.   Renal failure, blindness, 
heart disease, neuropathy, and atherosclerosis continue to afflict diabetics despite insulin therapy 
[2].  The ability of the islets of Langerhans to exquisitely control carbohydrate metabolism 
cannot be fully accomplished by insulin injections alone, primarily due to lack of real-time 
feedback and consequently significant swings in blood glucose levels.  These shortcomings of 
insulin renewed interest in pancreas transplantation.  The first successful clinical pancreatic 
transplant was performed in 1967 [7].  The patient’s hyperglycemia was reversed until 
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 complications later forced removal of the graft.  Later attempts at pancreas transplantation 
proved more successful.  Over 1000 pancreas transplants are now performed annually, with a 
success rate of 70% [8].  A successful pancreatic transplantation renders the recipient free from 
any exogenous insulin injections with normal blood glucose and HbA1c levels [9].  The chronic 
effects of diabetes are lessened: diabetic retinopathy is partially reversed [10] and native renal 
structure is restored ten years post implant [11].  Transplant recipients report a higher quality of 
life [12].   
Pancreatic transplants have demonstrated some benefits over insulin injections for the 
alleviation of chronic ailments and improved quality of life.  Patient survival rates one year after 
pancreatic transplantation surpass 90% [13].  However, pancreatic transplantation has 
disadvantages.  Successful transplantation typically requires simultaneous transplantation of both 
the pancreas and kidneys.  This surgery is plagued by complications resulting in prolonged 
hospital stays and repeat surgeries [14].  This in turn results in high costs. The diabetes 
community has thus begun focusing on transplanting solely the pancreatic islets.  The majority of 
the pancreas is an exocrine digestive gland; only 1-2% of the pancreas is composed of the islets 
that contain insulin-producing β-cells.   Transplanting solely the islets of the pancreas is a much 
less invasive procedure expected to be much safer and less costly to the patient [9].  Pancreatic 
islets removed from cadaver pancreata can be isolated using collagenase enzyme extracts to yield 
purified islets [14].  The first successful transplantation of islets into rats showed promise that it 
would soon become the definitive treatment for type 1 diabetes [15].  However, four years later 
the first clinical trial on seven diabetics using corticosteroid immunosuppression failed to render 
any of the seven patients insulin independent [16].  Success came with islet autotransplantation 
on patients undergoing a total pancreatectomy and infused with their own islets [17].  Without 
the need for any immunosuppressive drugs these patients with islet autografts delayed the onset 
of diabetes for over a decade [18].  Results with allografts – transplants from a different 
individual of the same species - have proven less promising.  Of the 237 adult islet 
allotransplants reported to the International Islet Transplant Registry (IITR) by December 31, 
2001 fewer than 12% remained free from insulin injections one year following transplantation 
[19].   
The failure of allotransplants to succeed while autotransplants thrived focused attention 
on the high levels of immunosuppressive drugs given to patients with allografts.  The potent 
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 immunosuppressive drugs tacrolimus (FK) and cyclosporine (CSA), regularly given to organ 
transplant recipients to prevent rejection, were found to be toxic to islets, causing distinct 
morphological damage to beta cells [20].  In 2000 researchers at the University of Alberta 
reported a modified protocol to treat seven patients with type 1 diabetes.  The equivalency of two 
donor pancreata were infused into patients via a percutaneous transhepatic portal embolization.  
Transplant recipients were given a glucocorticoid-free immunosuppressive regimen of sirolimus, 
tacrolimus, and daclizumab.  All seven patients attained insulin independence following 
transplant and maintained freedom from insulin injections one year post op [1].  The modified 
protocol has subsequently been called the Edmonton Protocol.  A major multi-center study is 
now being conducted to test the feasibility of the Edmonton Protocol.  A 90% success rate was 
recently reported by three participating centers with extensive experience in islet isolation [21].   
 
Bioluminescence 
 Bioluminescence manifests in nature in a variety of forms.  An assortment of organisms 
emit visible light, ranging from the ubiquitous firefly to marine bacteria.  Organisms exhibit 
bioluminescence for a variety of reasons: courtship and mating signaling, luring prey, defense, 
camouflage, and in response to stress [22].  This natural phenomena has been harnessed for use 
in research as an optical reporter tool. 
 Bioluminescence results from interaction of the luciferase enzyme with the substrate 
luciferin in the presence of oxygen.  A wide range of luciferase enzymes exist, each of which 
catalyze the oxidation of luciferin with corresponding release of photons of light.  The luciferase 
enzyme found in the firefly, Photinus pyralis, catalyzes bioluminescence in the presence of ATP 
through the following reaction [23].   
 
Luciferase + Luciferin + ATP + O2 ⎯⎯ →⎯ +2Mg  Luciferase-Luciferin + AMP + PPi        (1) 
Luciferase-Luciferin  + AMP + O2     ⎯→   Oxyluciferin* + CO2 + AMP         (2) 
Oxyluciferin*  Oxyluciferin + hν             (3) ⎯→
  
In the presence of oxygen, magnesium, and ATP, the reaction of the luciferase enzyme with the 
substrate luciferin yields an electronically excited oxyluciferin.  The return of oxyluciferin to its 
ground state is accompanied by the release of a single photon [24].  Thus, in the presence of 
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 excess luciferin, oxygen, and ATP, the number of photons emitted is proportional to the number 
of molecules of luciferase present [25].   
 Firefly luciferase was first purified and characterized in 1978 by Gates, et al.  [26].  The 
cDNA for firefly luciferase was then cloned in 1987 for use as an optical reporter [27].  This 
luciferase cDNA was inserted into monkey kidney cells and incorporated into the cell’s DNA. 
The luciferase enzyme was produced and sequestered in the peroxisomes of cells; subsequent 
luciferin entry into the cell catalyzed a bioluminescent reaction [28].  Since then luciferase has 
been used as an optical reporter gene in a wide variety of applications.  Luciferase has been used 
to study protein site-specific secretion, protein targeting, transgenic promoter activation, ATP 
and free Ca2+ concentrations, and the immune response [22].  A notable application of 
bioluminescence imaging is the visualization of  gene expression in individual cells in real time.  
Real time gene expression was first performed by tagging shuttle vectors with luciferase DNA 
and checking for functional coding sequences by visualizing luminescence on photographic film 
[29].  Since then, luciferase imaging has been used to monitor gene expression in a wide range of 
studies.    
 Bioluminescence imaging has long been used as a means of imaging cells in vitro.  
However, bioluminescent signals from sources deep within an animal are subject to attenuation 
by tissues overlying the source, previously preventing bioluminescence imaging on whole live 
animals.   The recent advent of ultra-sensitive charge coupled device (CCD) cameras capable of 
single photon counting has enabled in vivo imaging of bioluminescence.  CCDs consist of an 
array of capacitors that accumulate electric charge proportional to the light intensity at that 
location in the array.  The liquid nitrogen-cooled, back-thinned, back-illuminated CCD camera 
has a quantum efficiency (QE) of 85%, an order of magnitude better than the QE of intensified 
CCDs previously used in bioluminescent imaging [30].  Cooling the camera with liquid nitrogen 
reduces the dark noise on the chip to near negligible levels.  These advances in CCD detector 
sensitivity now allow in vivo bioluminescence imaging (BLI) of luciferase expression.  Gene 
expression in mice can be tracked externally by tagging viral vectors with the luciferase gene and 
imaging light emission following luciferin injection [31].  BLI has been used to non-invasively 
track tumor metastasis, with light emission directly related to tumor volume [32].  Other BLI 
applications include transplant studies, in vivo gene expression studies using a variety of 
transgenic animal models, and host-pathogen interactions [31]. 
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  Optical imaging holds several advantages over traditional imaging modalities such as 
MRI or CT.  The CCD cameras used for optical imaging cost less than MRI and CT equipment.  
Imaging times are shorter and multiple animals can be imaged at once.  Operation of CCD 
cameras is typically easier than that of other modalities, permitting use by a non-specialist.  
Optical imaging also permits quantification of metabolically active cells and permits the 
visualization of gene expression [30].  Lastly, optical imaging is inherently more sensitive than 
any other imaging modality.  For the purpose of this study, bioluminescence imaging is superior 
to other optical methods, such as fluorescence.  Fluorescence requires excitation light to 
stimulate light emission; bioluminescence is the product of a reaction requiring no excitation 
light.  The wavelengths of light needed for fluorescence excitation fall in the blue spectrum of 
light, wavelengths that are highly attenuated by blood and tissue.  In contrast, the emission 
spectrum of bioluminescence is broad, ranging from 500 to 700 nm, with a peak around 560 nm 
[30].  These higher wavelengths are attenuated less by tissue; thus bioluminescence can be 
detected from much deeper sources (several centimeters) than fluorescence.  Furthermore, 
bioluminescence is not subject to bleaching and auto-fluorescence issues that can skew 
fluorescence measurements.  Fluorescence measurements must take into account the number of 
excited cells as well as intensity of excitation light.  Quantification of bioluminescence is easier: 
light emission is directly proportional to the amount of luciferase, which in turn is proportional to 
the number of cells [30].   
 
Tissue Optics 
 Detailed knowledge of tissue optics is essential for quantitative interpretation of measure 
bioluminescence signals.  Photon-counting measurements must take into account the tissue 
optics governing light transmission from the luminescent source to the imaging system.  The 
propagation of light through biological tissue is governed by the interaction between tissue 
optical properties and sample geometry.  The movement of photons through a turbid biological 
media is influenced by scattering and absorption events within the tissue and reflection and 
transmission events at tissue boundaries.  These phenomena have been studied in depth and can 
now be mathematically analyzed and modeled.   
 Reflection of light occurs at the boundary between media with different optical 
properties.  The amount of light reflected depends on the angle of incident light and the index of 
 6
 refraction of each medium.  Index of refraction is a measure of the speed of light travel through a 
medium.  Index of refraction, n, is given as the ratio of the speed of light in a vacuum to the 
speed of light within the media, 
v
cn =                                                                      (4) 
where c is 3 * 108 m/s.  The specular reflection at the boundary between two media is given by 
Fresnel’s equation, 
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in which θ1 is the angle of incidence and θ2 is the angle of transmittance.  For beams normal to 
the surface (θ1 = 0) this equation reduces to 
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where n1 is the incident index of refraction and n2 is the index of refraction of the tissue medium.  
For a typical tissue air (n = 1.0) tissue (n = 1.33) interface, the reflection is 2%.  Reflection is 
maximized in a phenomenon known as total internal reflection, in which all light is specularly 
reflected and no light transmission occurs.  Total internal reflection occurs when the incident 
light occurs at an angle greater than some critical angle: 
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Reflection at tissue boundaries decreases the total amount of light transmitted into the tissue 
initially (known as specular reflectance) as well as at subsequent tissue boundary interactions 
(diffuse reflectance). 
 Upon entering a biological medium, protons can be absorbed by the tissue components 
and converted to heat, catalyze a chemical reaction, or be released as fluorescence emission.  
This absorption of light by tissue is utilized in many biomedical optics applications, including 
photodynamic therapy, photothermal ablation, and diagnostic spectroscopy [33].  Molecules that 
absorb light are known as chromophores; for visible light hemoglobin and melanin are the 
principle chromophores.  Light absorption is governed by the probabilistic exponential decay of 
Beer’s law.  Beer’s law depends on the concentration of the absorbing medium, c, and the 
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 molecular absorption coefficient, ξ(λ), a wavelength dependent property.  Beer’s law gives the 
loss of initial light intensity, I0, as a function of tissue depth: 
                                                           0)( Icdz
dI λξ−=                                                        (8) 
Molecular absorption coefficient and concentration are typically combined in one parameter, µa, 
the wavelength dependent absorption coefficient.  The mean free path, also known as penetration 
depth, is equal to the inverse of the absorption coefficient.  This depth is the point at which 63% 
of the incident light has been absorbed.   
 Photons are scattered in media with spatial fluctuations in density and refractive index, n, 
resulting in changes in photon path direction.  In biological tissue, discrete particles such as cell 
membranes, nuclei, collagen, or other cellular microstructure can cause photon scattering.  Two 
forms of scattering can occur: elastic scatter, in which no photon energy is lost; and inelastic 
scatter, in which some photon energy is transferred to the scattering molecule.  Inelastic scatter 
results in the Stokes shift, a phenomena exploited in Raman spectroscopy.  Elastic scatter simply 
results in the impinging photon redirected in a new path.  Scattering is treated much like 
absorption, a probabilistic approach using exponential decay.  The scattering coefficient, µs, 
gives the probability of a photon being scattered per infinitesimal distance.   
The direction of photon scattering is a complex estimate governed by a phase function.  
Assuming isotropic tissue optical properties, for a given photon moving in direction scattered 
to new direction  
sr
s ′r
                                                         π4
1),( =′ssp rr                                                            (9) 
In reality, light scattering in biological tissue is not isotropic.  The directional dependence of 
photon scatter is quantified by an anisotropy factor, g, which correlates to the cosine of the 
expected scattering angle.  Integrated over an entire sphere: 
                                                    ω
π
dsssspg ))(,(
4
′⋅′= ∫ rrrr                                                 (10) 
Values of the anisotropy factor range from 1, indicating completely forward scatter, to    –1, 
indicating completely backward scatter.  For biological tissue, g ranges from 0.7 to 0.99, 
indicating forward dominated scatter.  The contribution of the anisotropy factor is included in the 
reduced scattering coefficient: 
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This reduced scattering coefficient, ′sµ , is combined with the absorption coefficient into the 
effective attenuation coefficient: 
                                                                              ⎟⎠
⎞⎜⎝
⎛ ′+= saaeff µµµµ 3                                                (12) 
This can then be used to calculate the effective penetration depth: 
                                                             
eff
eff µδ
1=                                                           (13) 
This distance represents the distance required for intensity to be reduced to 37% of the initial 
intensity.   
The light transport equation provides a general solution for light propagation in turbid 
media: 
                 ),(),(),(),(),(),(
4
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ds
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π
             (14) 
Simply put, the gradient of the radiance at point r in direction s ′r  equals the (negative) loss due to 
absorption, minus the loss due to scattering, plus the gain from scattering, plus the power source 
at point r in direction .  This theory assumes steady state, homogenous optical properties, 
isolated particles, and no polarization or collimation.  Tissue is approximated as a finite plane 
parallel slab with finite thickness.  While the light transport equation is not easily solved, a 
number of mathematical models of the light transport equation exist.  Monte Carlo simulation, 
Adding-Doubling Method, Diffusion Approximation Theory, and Kubelka-Munk Theory each 
provide a solution method applicable with unique boundary conditions [33]. 
s ′r
 Determining the optical properties of biological tissue poses a difficult problem.  In vivo 
optical properties are difficult to measure, while in vitro optical properties are not known with 
great accuracy due to the shortage of adequate techniques [33].  For optically thin tissue samples 
with single scattering events, light absorbed and scattered can be directly measured using a 
reflection and transmission detector.  For thicker samples a double integrating sphere is 
employed.  A sample is placed between two spheres and a light source is shone on the tissue.  
One detector measures diffuse reflectance while another measures light transmission.  The 
reflection and transmission values at each wavelength can then be used to inversely solve the 
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 light transport equation iteratively to find the fundamental optical properties.  Optical properties 
of an in vitro tissue sample can also be determined using the ‘added absorber’ method.  An 
optical absorber is added in known concentrations to a bulk tissue, increasing absorption but not 
affecting scattering.  Absorption and scattering coefficients can be estimated by plotting µeff 
versus absorber concentration [34].  In vitro measurements of optical properties are not 
necessarily valid for the same tissue in vivo.  Biochemical and morphological changes 
accompanying tissue excision, temperature fluctuations, and changes in hydration can all affect 
optical properties of biological tissue [35].  A fiber optic probe can be used to measure the spatial 
distribution of fluence in a tissue in vivo.  The fluence mapping can be modeled to determine 
absorption and scattering coefficients.  Diffuse reflectance measurements can be performed non-
invasively using a fiber optic probe; the spatial distribution of these measurements can be 
modeled and used to estimate optical properties.  Although less refined than the photometric 
measurements outlined above, photothermal techniques for measuring optical properties are 
under development.  Pulsed photothermal radiometry measures the radiative heat flux from an 
irradiated tissue to indirectly estimate optical properties of strongly absorbing tissues.  
Photoacoustic spectroscopy (PAS) measures acoustic pressure waves emitted from irradiated 
tissue.  The amplitude and phase of the acoustic wave can then be used to estimate optical 
properties.   
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CHAPTER II 
 
ASSESSMENT OF PANCREATIC ISLET TRANSPLANTS USING IN VIVO 
BIOLUMINESCENCE IMAGING 
 
Abstract 
 Pancreatic islet transplantation is a promising treatment for type 1 diabetes.  However, 
current efforts to study islet transplantations are hampered by the lack of a non-invasive method 
of imaging islets and quantifying islet mass post transplantation.  Transplanted pancreatic islets 
can be imaged and quantified non-invasively using in vivo bioluminescence imaging (BLI).  
Pancreatic islets transfected with the firefly reporter gene, luciferase, emit light that can be 
quantified using photon-counting measurements.  Pancreatic islet number is linearly related to 
light emission both in vitro and in vivo.  Application of bioluminescence imaging for this 
application can be greatly enhanced by relating light emission to the number of islets surviving 
post-transplantation.  Determining this relationship requires detailed knowledge of the factors 
that influence photon-counting measurements.  Bioluminescence was modeled using constant 
light emitting phosphorescent beads implanted at the two common sites of islet transplantation: 
the renal capsule and liver.  This model was used to quantify light attenuation by tissues 
overlying the islet transplantations.  The ratio of implanted light emission to in vitro light 
emission was found to be .2394+/- 0.0261 for renal implantation and 0.0645 +/- 0.0140 for 
hepatic implants.  Mathematical modeling of light propagation using Monte Carlo simulation is 
in excellent agreement with these experimental results.  Monte Carlo modeling yields an in vivo 
to in vitro luminescence ratio for renal and hepatic sources to be 0.2860 and 0.0495, respectively.  
Surgical artifacts were found to influence bioluminescence measurements.  Surgical scar tissue 
leads to lower light emission the week immediately post-op, but this attenuation is negligible two 
weeks after surgery.  The orientation of the subject also influences quantification of 
bioluminescence.  Rotation of 50 degrees from flat can lead to a 73% decrease in light 
transmission for renal implants and 52% decrease for hepatic implants.  The rate of luminescence 
decrease with increasing angle depends on the surface light is projected upon.  Flatter surfaces 
lead to a slower decrease in luminescence while higher curvature leads to more rapid decrease in 
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 luminescence.  Spot size of bioluminescence was found to increase with increasing tissue depth.  
The spot size of hepatic implants was found to be 17% larger than renal implants, as measured 
by full width at half maximum measurements.  Constant light emission modeling of transplanted 
islet bioluminescence permits quantification of actual islet number from photon counting 
measurements and insight into factors which influence these measurements.   
   
Introduction 
 Pancreatic islet transplantation is showing promising results in the treatment of type 1 
diabetes.  The success of islet transplants using the Edmonton Protocol has given hope that 
transplantations may one day replace insulin therapy as the definitive treatment for type 1 
diabetes [1].  The success of the Edmonton Protocol is now being tested in a large multi-center 
trial [21].   Islet transplantation not only frees diabetics from daily insulin injections, but may 
also ameliorate some of the chronic pathologies associated with diabetes [2].  The ability of 
transplanted pancreata to exquisitely regulate blood glucose levels results in partial reversal of 
diabetic retinopathy [10] and restoration of native renal structure [11].   
 Despite advances in immunosuppression and islet isolation utilized by the Edmonton 
Protocol, islet transplantation is not ready to be adopted as a routine clinical treatment for type 1 
diabetes.  One major obstacle facing islet transplantation is a shortage of islets.  Successful 
reversal of diabetes requires transplantation of a large quantity of islets, typically the equivalent 
of two pancreata.  The supply of islets available for transplant falls well short of the amount 
needed to treat the estimated 17 million type 1 diabetics in the United States [2].  The need for 
immunosuppressive therapy following transplantation is another complication facing islet 
transplantation.  The side effects of immunosuppressive medications can prove worse than the 
effects of diabetes.   
The challenge is now to successfully reverse diabetes while transplanting fewer islets.  
Considerable research efforts are currently underway to sustain or increase islet mass post 
transplantation.  However, these efforts are hampered by the lack of an adequate method of non-
invasively quantifying islet mass post transplantation.  Current methods of estimating islet mass 
are insufficient.  Insulin secretion following glucose challenge gives insight into islet function, 
but not necessarily islet mass.  Morphometric analysis of excised islet grafts requires sacrificing 
the animal, preventing sequential measurements.  While useful for islets transplanted beneath the 
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 renal capsule in rodents, morphometric analysis proves difficult for islets scattered throughout 
the liver, the site of human islet transplantation.   
 This study investigates the use of in vivo bioluminescence imaging (BLI) to track 
transplanted pancreatic islet mass.  Pancreatic islets were transfected with a replication-deficient 
adenovirus carrying the luciferase reporter under control of a constitutive CMV promoter.  The 
oxidation of luciferin by the luciferase enzyme generates bioluminescence in the presence of 
ATP and oxygen [23].  These bioluminescent islets were transplanted into the renal capsule or 
liver of NOD-SCID mice, an immune deficient mouse model that accepts xenografts.  The light 
emission from islet grafts could then be imaged and quantified by an ultra-sensitive CCD camera 
[31].   
 Correlation of light emission to islet mass must take into account the factors that 
influence light transmission from the bioluminescent source to the CCD camera aperture.   
Light transmission is determined by the optical properties of the tissue through which the light 
passes.  Constant emission, isotropic light emitting beads with spectral emission similar to the 
luciferase reaction were implanted beneath the renal capsule or liver of NOD-SCID mice.  These 
beads serve as a model of islet bioluminescence, providing a constant light source from the 
location of the islet grafts.  The luminescent beads provide a constant, known light intensity that 
is reliable and reproducible, allowing for validation of the imaging system.  In contrast, 
bioluminescent islets are subject to biological variability.  Islet light emission depends on the 
health and size of the islets and survival of islets post transplantation.  The constant bead light 
emission was used to quantify the variability inherent in bioluminescence imaging.  The effects 
of wound healing, mouse positioning, and light attenuation by tissues overlying the islet grafts 
were determined by imaging these bead-bearing mice.  These factors must be taken into account 
when correlating light emission to islet mass.  These findings hold important clues for 
quantitative interpretation of bioluminescence imaging applicable to any study involving 
quantification of bioluminescence.   
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 Materials & Methods 
Animal Model 
 NOD-SCID mice were obtained from Jackson Laboratories (Bar Harbor, Maine).  The 
NOD-SCID strain is homozygous for the severe combined immune deficiency (SCID) 
spontaneous mutation, characterized by an absence of functional T cells and B cells.  The NOD-
SCID strain accepts allografts with no immune rejection response.  NOD-SCID mice do not 
become diabetic or develop insulitis.   
 
Mouse Islet Isolation 
 The splenic portion of a mouse pancreas was dissected and infused with 3 ml of 
collagenase P  (Roche Molecular Biochemicals, Indianapolis, IN) in Hanks buffered saline (0.6 
mg/ml) through the bile duct.  Groups of two pancreata were then digested in 6.7 ml of 
collagenase P (0.6 mg/ml) for 4-5 minutes at 37°C using a wrist action shaker.  Some islets were 
then handpicked under microscopic guidance.  Others were purified by histopaque gradient 
centrifugation and washed 3 times with 10 mM PBS containing 1% mouse serum.  Islets were 
suspended in 30 µL of 10 mM PBS with 1% mouse serum solution.   
 
Human Islet Isolation 
 Human pancreatic islets were obtained from Dr. David Harlan at NIDDK/NIH and from 
the JDRFI Islet Distribution Network.  Islets were isolated from the cadaver of human organ 
donors and placed on ice (cold ischemia time < 8h).  Islets were digested with a 4°C solution of 
Liberase HI (Roche Molecular Biochemicals, Indianapolis, IN) injected into the pancreatic ducts 
coupled with mechanical agitation by shaking. Islets were purified from other pancreatic 
fragments by density gradient separation.  Islets were shipped on ice the same day by overnight 
courier.   
 
Islet Luciferase Transfection 
 Islets were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) with 10% Fetal Bovine 
Serum (Invitrogen, Carlsbad, CA) and 11mM glucose.  Islets were infected with an adenovirus 
(MOI = 1000) expressing the dual reporter genes luciferase and green fluorescence protein 
 14
 (GFP).  They were then placed in cell culture for 12 hours.  Islets were suspended in 30 µL of 10 
mM PBS with 1% mouse serum solution.   
 
Kidney Islet Transplantation 
 Mice were anesthetized with an intraperitoneal injection of 50 mg/kg b.w. sodium 
pentobarbital (Abbot Laboratories, Chicago, IL).  The left flank was then shaved, prepped with 
ethanol, and draped in sterile fashion.  A left flank incision overlying the kidney was performed.  
The left kidney was then exposed and irrigated with saline.  The islet suspension (30 µL) was 
injected between the renal capsule and parenchyma of the kidney using a 23-gauge butterfly 
needle.  The needle was withdrawn and the insertion point was cauterized.  The wound was 
closed with black subcutaneous sutures (Prolene, Ethicon, Somerville, NJ) and aluminum skin 
staples (Autoclips, 9 mm size, Clay Adams, Parsippany, NJ).   
 
Liver Islet Transplantation 
 Mice were anesthetized with an intraperitoneal injection of 50 mg/kg b.w. sodium 
pentobarbital.  The abdomen was then shaved, prepped with ethanol, and draped in sterile 
fashion.  A lateral incision was made in the abdomen above the liver.  Islets were infused into the 
portal vein via PE10 tubing attached to a 30-½ gauge needle.  Slight pressure was applied to the 
insertion point to stop blood loss.  The abdominal incision was closed with subcutaneous sutures 
and skin staples, as described above.   
 
Bioluminescence Imaging of Islets 
Bioluminescence imaging was performed using a back thinned, back illuminated charge 
coupled device (CCD) camera with a 1300x1340 pixel chip (Roper Scientific, Trenton, NJ).  
Prior to imaging, the camera chip was cooled to -90°C by the addition of liquid nitrogen.  A one-
millisecond background image was taken to find the background readout noise on the chip. The 
background image was subtracted from the bioluminescence image to remove background noise.  
On chip binning of 5 was used for all images to increase signal to noise ratio.  Twenty-five pixels 
(a 5 x 5 square) were combined to generate one pixel.  Image integration time was 4 minutes.  
An overlay image (black and white picture) was taken with a light inside the imaging chamber 
turned on to illuminate the subject.  The luminescence image with peak intensity was used for 
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 image analysis with Metamorph software (Version 4.6r6, Universal Imaging Corporation, 
Downingtown, PA).  Using Metamorph, regions of equal area were drawn around the region of 
interest (ROI).  Luminescence was quantified by summing pixel intensities within the region to 
yield integrated intensity.   
 
In Vitro Bioluminescence 
 Islets were preserved in 30 µL of 10 mM PBS with 1% FBS (Invitrogen, Carlsbad, CA) 
and kept on ice prior to imaging.  Islets were then placed in 6 well plates with 100 µl of PBS.  
The bioluminescence substrate D-Luciferin (Promega, Madison, WI) was added in excess (10 µL 
of 0.15 mg/ml concentration) to each well.  The well plate was placed in the light tight box of the 
camera system.  Bioluminescence was imaged by a four-minute exposure taken with the CCD 
camera.  Another four-minute exposure image was taken following the first, in order to capture 
the peak in luciferase activity.  For in vitro luminescence, the peak luminescence always 
occurred in the initial 4 minutes following substrate addition.   
 
In Vivo Bioluminescence  
 Mice were anesthetized prior to imaging with an intraperitoneal injection of 50 mg/kg 
b.w. sodium pentobarbital.  The hair overlying the islet graft was shaved to reduce light 
scattering.  The substrate D-luciferin dissolved in sterile de-ionized water was added by 
intraperitoneal injection of 150 mg/kg b.w.  Mice were secured to a black felt pad using Velcro 
to minimize any motion artifacts during imaging.  This pad was then placed in the light tight 
imaging chamber.  A bioluminescence image with four minute exposure time was taken, 
followed by another four minute exposure image.  The peak luminescence image for in vivo 
bioluminescence was typically the second image taken.   
 
Luminescent Beads 
 Luminescent beads were obtained from Mb-Microtec (Bern, Switzerland).  These beads 
consist of glass capillaries (0.9 mm diameter and 2 mm long) filled with tritium (a β-emitter with 
a half life of over 10 years) that excites a phosphor and emits constant intensity light.  The 
spectral emission of these beads was measured using a fiber optic probe attached to a 
spectrometer (Ocean Optics Inc., Dunedin, FL) equipped with a 360 nm cutoff filter.  Spectral 
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 emission of a single bead within a centrifuge tube was measured with one-second integration 
time.  An attached laptop computer was used to record the spectral data.   
 
Bead Transplantation 
Mice were anesthetized with an intraperitoneal injection of 50 mg/kg b.w. sodium 
pentobarbital (Abbot Laboratories, Chicago, IL).  An incision was made above either the kidney 
or liver, as in the islet transplantations.  The luminescent bead was glued onto the kidney or liver 
at the site of islet engraftment using Vetbond™ tissue adhesive (3M, St. Paul, Minnesota).  The 
incision was closed with subcutaneous sutures and skin staples as before. 
 
Imaging of Luminescent Beads 
 Imaging of luminescent beads was carried out using the charge coupled device (CCD) 
camera used for islet imaging.  Beads were placed on a black felt pad within the light tight box.  
A background image of 1 ms was taken for background noise subtraction.  Beads were then 
imaged with a 1 second exposure time.  Beads were re-imaged 4 times, reorienting the bead 
between each image, in order to quantify variability in bead light emission.  Bead luminescence 
was quantified using Metamorph software.  Equal area regions were drawn around the beads and 
photon count was quantified by summing pixel intensities within the region.  After bead 
implantation each mouse was imaged weekly for 6 weeks.  A one second exposure was used for 
all bead images.  Implanted bead luminescence was quantified by photon counting, as in the islet 
experiments.  Spot size was determined using Metamorph.  The maximum intensity pixel from 
each implanted bead was found and measured.  A threshold was then applied at half the 
maximum intensity for all pixels above that value.  The number of pixels exceeding threshold 
was determined.  This area is the spot size; full width at half maximum (FWHM) was calculated 
as the diameter of this circular spot size.   
π
thresholdAreaFWHM ⋅= 4               (15) 
 
Rotational Variability Study 
 The rotational variation in implanted bead intensity was measured using a rotational 
stage.  This stage consisted of a hinged black felt platform that allowed 50 degree rotation in 
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 either direction (Figure 1).  Mice with luminescent beads were attached to the stage using Velcro 
and placed in the light tight imaging box of the CCD camera.  Mice with the bead on the renal 
capsule were placed in a lateral decubitis position (bead facing up); mice with hepatic beads 
were placed in the supine position.  The stage was rotated in ten degree increments from –50 
degrees to 50 degrees (with 0 degrees indicating parallel to the floor).  Positive rotation was 
defined as clockwise rotation when viewed from the head of the mouse.  Thus for renal beads 
positive rotation was defined as rotation toward the prone orientation, while negative rotation 
indicated rotation towards the supine orientation.  One-second camera exposures were taken at 
each angle.  Luminescence was quantified using Metamorph’s photon counting, as previously 
described.  Luminescence at each angle was normalized to light intensity at 0 degrees.   
θ
θ
Camera
Figure 1:  Image and schematic of a mouse with a hepatic bead on the rotational stage.  Mice were attached 
rigidly to the stage via Velcro.  The stage could then be rotated with respect to the camera axis 50 degrees 
from flat in either direction.  Ten-degree increments were marked beneath the stage to delineate the angle of 
rotation.   
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 Monte Carlo Simulation 
 Monte Carlo simulation was used to model the propagation of photons from the 
luminescent bead to the aperture of the CCD camera.  Monte Carlo simulation provides a well-
accepted numerical simulation of light transport in multi-layer tissues close to tissue boundaries 
[36].  Transmission of light through the tissue was determined as a function of radial position; 
photon transmission reaching the camera aperture was calculated as the photon weight 
transmitted within the radius of the camera aperture.  Monte Carlo simulation was run for three 
conditions: the bead alone, the bead implanted in the renal capsule, and the bead implanted 
beneath the liver.  The bead simulation consisted of a single layer of non-absorbing, non-
scattering media corresponding to the air between the camera stage and aperture.  The renal bead 
simulation added a layer of skin to the air layer.  The hepatic bead simulation added a layer of 
liver tissue to the skin and air layers for a three-layer model.  Thickness of the tissue layers was 
determined by sacrificing the animal and measuring tissue thickness overlying the bead using 
calipers.   
Camera
Bead
50 cm
5 cm
Stage
 
Figure 2.  Schematic of geometry used in Monte Carlo simulations.  The luminescent bead was modeled as an 
isotropic light source.  A 50 cm gap of air separated this light source from the camera.  Light transmission 
was summed for photons reaching the inner 2.5 cm radius corresponding to the camera aperture.   
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Table 1.  Optical properties used in Monte Carlo simulations.  Simulation of the bead alone consisted of a 
single layer model consisting of only the air layer between the camera stage and aperture.  Simulation of the 
renal bead consisted of the skin layer overlaying the bead and the air layer.  Simulation of the hepatic bead 
used the three-layer model including optical properties of the liver overlying the bead, as well as the skin and 
air layers.   
 
 Thickness [cm] n g µa [cm-1] µs [cm-1] 
Air 50 1 1 1E-09 0 
Skin 0.025 1.37 0.9 1 90 
Liver 0.1 1.37 0.9 9.6 89 
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Results 
 
 
Figure 3:  Image of bioluminescent human islets in a 6-well plate.  The plates contain (clockwise from lower 
left): 1000 islets with no virus, 0 islets, 50 islets, 1000 islets, 500 islets, and 100 islets.  Image was taken with a 
CCD camera with a four-minute exposure time and binning of 2. 
 
 
Bioluminescent Islets 
 Bioluminescent islets can be imaged in vitro using an ultra-sensitive CCD camera for 
photon detection.  Addition of the substrate luciferin to islets expressing luciferase induces 
bioluminescence (Figure 2).  Bioluminescence intensity increases as the quantity of islets in the 
well plate increases.  This bioluminescence can be quantified by photon counting of the glowing 
area.  As shown in Figure 3, islet bioluminescence correlates linearly to islet number in vitro.   
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Figure 4:  Plot of bioluminescent intensity of in vitro murine islets in a 6-well plate.  Image was taken with a 
CCD camera with a four-minute exposure time and binning of 5.  The coefficient of determination (R2) is 
0.9636.  Shown is the mean of 4 wells for each islet number plus or minus the standard error of the mean.   
 
 
 Bioluminescent islets transplanted beneath the renal capsule of NOD-SCID mice can be 
imaged using a CCD camera.  Intraperitoneal injection of the substrate luciferin into mice 
bearing bioluminescent islets induces bioluminescence detectable from outside the mouse.  This 
luminescence can then be quantified using photon counting of the glowing region.  
Bioluminescence intensity correlates linearly to the number of islets transplanted (Figure 4).     
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Figure 5:  Plot of transplanted islet equivalency (IEQ) vs. bioluminescence intensity.  Mice were transplanted 
with human islets (courtesy of NIH islet isolation facility) under the renal capsule.  Images were taken 4 
weeks post transplantation.  Image was taken with a CCD camera with a four-minute exposure time and 
binning of 5.  Shown is the mean of 3 or 4 mice at each islet number plus or minus the standard deviation.  
The coefficient of determination (R2) is 0.9946. 
 
 
Two different anatomical sites are typically used for murine islet transplantation.  Islets 
transplanted beneath the renal capsule form a stable islet graft in a small area.  However, liver 
transplantation is more applicable to clinical studies, as the liver is the site of human islet 
transplantations.  Islets transplanted into the renal capsule undergo different optical interactions 
than those transplanted into the liver.  As seen in Figure 5, light emission from hepatic islets is 
significantly less than that from renal islets.  Light traveling from the liver must penetrate 
through more tissue than light propagating from the kidney.   
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Figure 6:  Image of mice with 100 transplanted bioluminescent islets.  Image was taken with a CCD camera 
with a four-minute exposure time and binning of 5.  The mouse on the left was transplanted with 100 murine 
islets under the renal capsule.  The mouse on the right was transplanted with murine 100 islets into the portal 
vein.  Both mice were imaged two weeks post transplantation.   
 
 
 
Luminescent Beads 
 Luminescent beads provide a constant light source with a half live of 10 years.  These 
luminescent beads were imaged in a CCD camera (Figure 6).  Light emission from these beads 
was quantified using photon counting.  The spectral emission of these beads was found using a 
fiber optic probe attached to a spectrometer.  As seen in Figure 7, the spectral emission of the 
luminescent beads is similar to that of the luciferase reaction.  The luminescent bead shows peak 
emission at 600 nm, slightly higher than the 563 nm peak emitted by the luciferase reaction.  But 
the bead spectrum provides a good replica of the luciferase reaction.   
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Figure 7:  Image of luminescent beads prior to implantation.  The left panel shows the scale of the beads.  The 
image in the right panel was taken with a CCD camera with a one second exposure time.  The units of the 
scale bar are photon counts per pixel.   
 
400 450 500 550 600 650 700 750 800
Wavelength [nm]
Luminescent Bead
Luciferase
Figure 8:  Spectra of luminescent bead prior to implantation and the luciferase reaction.  The spectral 
emission of these beads was measured using a fiber optic probe attached to a spectrometer (Ocean Optics 
Inc., Dunedin, FL) with one-second integration time.  The spectral emission of luciferase was plotted from 
commonly accepted data [30].    
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  Luminescent beads were implanted at the sites used for islet transplantation: at the renal 
capsule and underneath the frontal lobe of the liver.  Figure 8 shows a luminescent bead 
implanted at the renal capsule (left) and underneath the frontal lobe of the liver (right).  The renal 
bead shows a brighter, more concise region of luminescence.  Light emission from the hepatic 
bead is less bright and more diffuse.  Note the difference in scale between the two images.   
 
 
2000
0
500
0
Figure 9:  Image of luminescent bead implanted at the renal capsule (left) and underneath the frontal lobe of 
the liver (right).  Note the differences in scale.  Image was taken with a CCD camera with a one second 
exposure time.   
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  Mice with luminescent beads implanted at the renal capsule were imaged weekly for 6 
weeks to determine the temporal variation in luminescence intensity.  At one-week post 
implantation, the mice with renal beads showed significantly lower luminescence than in latter 
weeks (t test, α = 0.05).  By 6 weeks post implantation luminescence had more than doubled.  
Six weeks post transplantation the ratio of bead luminescence while implanted to bead 
luminescence pre-implantation was 0.2394 +/- 0.0261.  The renal beads also showed more 
variation in the week immediately post operation.  By the second week post implantation this 
variation had decreased by 45%.   
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Figure 10:  Intensity of luminescent beads implanted in the renal capsule as a function of time.  Luminescence 
intensity was measured using a CCD camera (Roper Scientific, Trenton, NJ) with a one second exposure 
time.  Intensity is expressed as the ratio of bead intensity when implanted to the bead intensity pre-
implantation.  Mice were imaged weekly following bead implantation.  Shown are the mean and standard 
error of the mean of 4 mice.   
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  Luminescent beads implanted beneath the liver showed a similar pattern temporally.  The 
first week luminescence was lower than latter weeks.  By the sixth week, the ratio of hepatic 
bead intensity to bead intensity pre-implantation had reached a steady state value of 0.0645 +/- 
0.0140.     
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Figure 11:  Intensity of luminescent beads implanted beneath the liver as a function of time.  Luminescence 
intensity was measured using a CCD camera (Roper Scientific, Trenton, NJ) with a one second exposure 
time.  Intensity is expressed as the ratio of bead intensity when implanted to the bead intensity pre-
implantation.  Mice were imaged weekly following bead implantation.  Shown are the mean and standard 
error of the mean of 3 mice.   
 
The luminescence from the renal and hepatic implanted beads was also analyzed for light 
scattering.  Spot size, full width at half maximum (FWHM), was determined at each week post 
implantation.  The beads implanted under the liver showed a greater spot size at each week 
(Figure 11).  By the sixth week post implantation, the FWHM of the liver implanted beads were 
17% higher than the FWHM of the renal beads.  As in the intensity measurements, the greatest 
variability was seen one week following surgery.   
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Figure 12:  Spot size of luminescent beads implanted in the renal capsule and beneath the liver as a function 
of time after implantation.  Spot size was measured using a CCD camera (Roper Scientific, Trenton, NJ) with 
a one second exposure time.  The maximum intensity pixel of each implanted bead was found using 
Metamorph (Version 4.6r6, Universal Imaging Corporation, Downingtown, PA).  A threshold at half of this 
maximum was applied for each implanted bead and area of threshold was measured using Metamorph.  The 
diameter of this circular spot size was calculated as full width half maximum (FWHM).  Spot size is expressed 
as the ratio of FWHM when implanted to the FWHM of the bead pre-implantation.  Mice were imaged 
weekly following bead implantation.  Shown are the mean and standard error of the mean of the renal 
capsule and hepatic mice, n = 4 and n = 3, respectively.   
 
Monte Carlo Simulation 
 Light propagation from the luminescent bead to the camera aperture was modeled using 
Monte Carlo simulation.  Simulation was run for the bead alone, for the bead implanted on the 
renal capsule, and for the bead implanted beneath the renal capsule.  The results of this 
simulation are shown in Table 2.  These results were compared to the experimental results of the 
bead implantations 6 weeks post implantation.  The two values show excellent correlation.   
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 Table 2:  Monte Carlo simulation of light propagation from the luminescent bead.  Light transmission 
through all tissue (and air) layers was calculated as a function of radial position.  Photon transmission at radii 
less then or equal to the radius of the camera aperture was summed to yield total photons reaching the 
camera.  These photon transmission values were used to calculate the ratio between the renal bead and bead 
pre-implantation, as well as the ratio between the hepatic bead and bead pre-implantation.  These values are 
shown along with the ratio between in vivo and in vitro bead luminescence found experimentally.   
 
 
 
 
Monte Carlo Simulation Bioluminescent Imaging 6 Weeks Post Implantation 
Ratio of Renal Bead Intensity to 
Bead Pre-Implantation 0.2860 0.2394+/- 0.0261 
Ratio of Hepatic Bead Intensity 
to Bead Pre-Implantation 0.0495 0.0645 +/- 0.0140 
 
 
 
Rotational Variation 
 The luminescence emitted from the implanted beads was also analyzed for rotational 
variation.  As shown in Figures 12 and 13, the luminescence intensity measured by the CCD 
camera changed as a function of rotational angle.  As the mouse was rotated from a flat position 
(lateral for renal beads, supine for hepatic beads) the luminescence intensity decreased.  At low 
angles, intensity decreased only slightly.  But at 50-degree rotation from flat, luminescence 
intensity decreased to approximately 0.27 of the flat intensity for the renal bead and 0.48 of the 
flat intensity for the hepatic bead.  The rotational variation was more pronounced for beads at the 
renal capsule than for hepatic beads.   
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Figure 13:  Intensity of luminescent beads implanted in the renal capsule as a function of position.   
Mice were placed laterally, with the implanted bead facing up, on a rotational stage.  The stage was rotated in 
10-degree increments from –50 degrees to 50 degrees.  Luminescence intensity was measured using a CCD 
camera (Roper Scientific, Trenton, NJ) with a one second exposure time at each angle.    Intensities were 
normalized to the intensity of each mouse when laying flat (angle of rotation = 0).  Shown are the mean and 
standard error of the mean for 4 mice. 
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Figure 14:  Intensity of luminescent beads implanted beneath the liver as a function of position.  Mice were 
placed supine on a rotational stage and rotated in 10-degree increments from –50 degrees to 50 degrees.  
Luminescence intensity was measured using a CCD camera with a one second exposure time at each angle.    
Intensities were normalized to the intensity of each mouse when laying flat (angle of rotation = 0).  Shown are 
the mean and standard error of the mean for 3 mice.   
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 Discussion 
 This study examines the use of in vivo bioluminescence imaging (BLI) for tracking 
transplanted pancreatic islets.  Islets infected with an adenovirus carrying the constitutively 
expressed reporter gene luciferase emit light when combined with the substrate luciferin.  This 
luminescence can be quantified using photon-counting measurements.  For a given set of 
transfection conditions, a linear relationship exists between the number of islets transplanted and 
the measured light produced by the bioluminescence reaction.  Transplanted islets can also be 
imaged in vivo even from deep tissues in small animals, showing distinct bioluminescent regions 
corresponding to the area of islet graft.  Quantification of photon emission in vivo shows a linear 
relationship between numbers of islets transplanted and light emission.   
 The linear relationship between number of bioluminescent islets and emitted light 
intensity is useful for comparing sets of transplants.  However, it is not necessarily applicable 
across studies in which imaging parameters and transfection efficiency may vary.  The measured 
light intensity depends on the transfection efficiency of the adenovirus, the size of the islets, and 
the parameters used in imaging, such as integration time and are of the integration region.  The 
parameter of interest when tracking transplanted islets is the number of islets surviving post-
transplantation.  The correlation of light emission to islet number in vivo enables the use of IBL 
as a non-invasive means of islet assessment in mouse models of diabetes and islet transplants. In 
turn, these models may be used as high throughput models for assessment and screening of novel 
therapeutic procedures aimed at increasing functional islet survival. While relative information 
regarding islet mass or numbers as function of time or in response to pharmacological 
intervention is readily obtained from the bioluminescence measurements (i.e. increase or 
decrease of signal), absolute information regarding the number or percentage of islets surviving 
requires more detailed investigation of the optics governing light transmission from the 
bioluminescent source to the CCD camera aperture.   
In order to model bioluminescence from islet grafts, luminescent beads were employed.  
These beads were implanted at the two common sites of islet transplantation: the renal capsule 
and liver.  The implanted beads mimic bioluminescence with constant and known intensity light 
emission from the site of islet grafts.     
As expected, light emitted from islet grafts is significantly lower than light emission from 
islets in vitro.  However, it was previously unclear how much of this decrease in luminescence 
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 was due to islet death post-transplantation and how much could be attributed to light attenuation 
by tissues overlying the implants.  Comparison of renal grafts to hepatic grafts shows a 
discrepancy between light transmission from each site.  Renal transplants are brighter and 
spatially more concise.  Transplantations into the liver are less bright and more diffuse.  The 
renal capsule implantation site is more superficial; the mean free path of light emitted from this 
site is shorter than light emitted from the liver.  Light emanating from the hepatic transplants 
must pass through liver tissue, a highly perfused tissue that contributes significant light scattering 
and absorption.  The light emitting beads transplanted at the site of islet grafts were used to 
quantify light transmission through the tissues overlying the luminescent source.  For renal 
implantation, the ratio between luminescence after implantation to luminescence of the bead 
alone stabilized to a constant value six weeks post-implantation.  This ratio was found to be 
0.2394+/- 0.0261.  Monte Carlo simulation of light transmission to the CCD camera yields an in 
vivo to in vitro ratio of 0.2744.  For hepatic implantation the ratio of light intensity from the liver 
bead to the bead alone was 0.0645 +/- 0.0140 six weeks post surgery.  Monte Carlo simulation of 
hepatic light transmission yields a ratio of 0.0667.  Experimental results for both renal and 
hepatic implanted beads are in good agreement with Monte Carlo modeling of photon 
propagation.  Light attenuation by tissue overlying hepatic transplants results in nearly four-fold 
less light transmission from hepatic islets than renal islets.  This ratio between in vivo and in 
vitro luminescence found using the constant intensity luminescent beads could then be compared 
to the ratio between islet bioluminescence in vivo and in vitro.  Preliminary results indicate that 
the ratio for islets is much lower, indicating a large (six to eight fold) drop in viable islets post 
transplantation.   
The luminescence from implanted beads was tracked temporally to investigate time 
dependent effects on light transmission.  Islets studies previously showed that transplanted 
bioluminescent islets show lower luminescence the week immediately following surgery.  The 
exact reason for this lower light emission was unknown.  It was thought that insufficient 
vascularization of the islets one-week post-op could hamper delivery of the substrate luciferin to 
the islet graft.  Scar tissue from suturing and stapling the skin overlying the islet grafts was also 
believed to absorb and scatter bioluminescence.  This affect of the inflammatory response on 
bioluminescence measurements is dynamic immediately post op as the wound healing process 
rapidly progresses.  One to two weeks post implantation the attenuation by scar tissue reaches a 
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 steady state as the wound heals.  Results from the bead implantations indicate that the latter 
explanation of low luminescence immediately following surgery is responsible.  Scar tissue 
above the luminescent source attenuates light transmission from the light source.  The mice with 
beads implanted at both the renal capsule and liver show lower luminescence the first week post 
transplantation.  Additionally, they show greatest variation in light transmission at one-week post 
implantation, a pattern repeated with the islet transplants.   
The spot size of luminescence differs between hepatic islets and renal islets.  Islets 
infused into the portal vein typically embolize throughout the liver, leading to a more diffuse 
light source.  Renal islets are typically isolated in a contiguous graft.   However, spot size is also 
a function of the tissue optics through which propagating photons pass.  Bioluminescence from 
the liver passes through hepatic tissue, leading to higher scattering and thus a larger spot size 
than renal grafts.  The extent to which increased hepatic light scattering leads to larger spot size 
was analyzed using the mice with implanted beads.  The full width at half maximum (FWHM) 
for the hepatic beads was 17% higher than the renal bead implants.  The islet transplants show a 
much larger spot for liver placement relative to renal, suggesting that (as expected) the liver 
islets are more spatially dispersed throughout the organ versus the renal capsule where the graft 
is clustered together. 
Bioluminescence measurements can be affected by rotation of the sample.  Detected 
photon emission depends on the angle of the surface normal makes with the optical axis of the 
camera system. Presumably the primary reason for this is the fact that light emission from a 
highly scattering medium resembles a Lambertian distribution with most of the light emitting in 
an angle normal to the surface [37].  The practical implication of this finding is that the exact 
positioning of the mouse relative to the camera axis is an important parameter that must be 
controlled carefully. Failure to do so can induce variations in the photon counting measurements 
from one time point to the next that are not representative of the biological processes for which 
bioluminescence is the surrogate marker.  The application of tomographic analysis to 
bioluminescence imaging, thus far still in a developmental state, must take into account these 
rotational effects.  The effect of rotation on luminescence measurements was determined for both 
renal and hepatic implanted beads.  At small angles, rotation had little affect on photon counting.  
However, at rotations of 50 degrees from flat, measured luminescence decreased to a third of the 
flat measurement for renal beads.  For hepatic beads, the decrease at 50 degrees from flat was 
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 slight less, but still resulted in measured intensity less than half of the flat.  Both implantation 
sites showed a parabolic relationship between angle and luminescence, with luminescence 
decreasing with increasing angle from flat.  However, the drop in renal intensity was sharper and 
more pronounced than that seen from the hepatic bead.  The hepatic bead implantation is imaged 
with a supine position indicating flat.  The renal bead was imaged with a lateral placement 
serving as flat.  Both of these placements were used to minimize the mean free path of light 
through tissue.  The supine placement has a much larger flat surface, while the lateral placement 
is subject to sharper curvature.  The liver bead thus has more surface area normal to the camera 
axis than the renal bead.  This results in a slower drop in luminescence with increasing rotation 
for the hepatic implantation.   
 
Conclusions 
Bioluminescence imaging can be used to non-invasively monitor transplanted pancreatic 
islets in vivo.  A linear relationship exists between number of luminescent islets and integrated 
photon counts in vitro.   This linear relationship holds for islets transplanted beneath the renal 
capsule, as well.  To fully utilize bioluminescence imaging as a modality for imaging 
transplanted islets, light intensity can be related to number of islets surviving post 
transplantation.  This requires investigation of the optical properties of tissue overlying the site 
of transplantation.   
Models of bioluminescence using constant light emission sources can yield critical 
information regarding light emission.  The attenuation of light by tissues overlying the renal 
capsule and hepatic islet transplantations was quantified.  Light emission from the renal capsule 
was approximately four times greater than light emission from a hepatic source.  The ratios of in 
vivo to in vitro luminescence found experimentally are in excellent agreement with Monte Carlo 
simulation of photon migration.  These ratios can be used, along with bioluminescence 
measurements of islets in vitro and in vivo, to correlate photon counting measurements to actual 
islet number surviving post-transplantation.   
Surgical artifacts can affect bioluminescence measurements.  Light emission the week 
immediately following surgery can be significantly lower than latter weeks due to post-surgical 
inflammation and scarring.  Scar tissue from sutures and surgical staples attenuates light more 
strongly than native skin, leading to lower measured bioluminescence.  This finding indicates 
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 that bioluminescence imaging may not accurately reflect islet mass until two weeks post 
transplantation.   
The spot size of light emission differs for renal and hepatic light sources.  Hepatic 
sources traverse highly vascular liver tissue, leading to higher scattering.  This results in spot 
size, measured as full width at half maximum, larger for hepatic sources.  However, the increase 
in hepatic spot size determined using luminescent bead was not as great as the increase in spot 
size between renal and hepatic islets, indicative of the dispersed nature of hepatic islet grafts.   
Bioluminescence measurements are affected by the orientation of the subject.  Rotation 
of the subject can lead to decreased photon-counting measurements.  This finding has application 
in everyday bioluminescence imaging, as subjects can exhibit motion artifacts during imaging, as 
well as development of tomographic bioluminescence imaging systems.  The rate of light 
intensity decrease with rotation angle is dependent on the source of luminescence.  Light 
projected on a flat surface undergoes less light decrease with rotation than surfaces with sharp 
curvature.   
Bioluminescence measurements are subject to some inherent limitations.  In vivo BLI can 
be applied only to small animal models; the tissue thickness of primate models prevents BLI 
studies.  Additionally, the islets constitutively express the reporter gene luciferase in all islet 
cells, not just β-cells.  In most islet transplantation studies, only the insulin producing β-cells are 
of interest.  The study is also subject to some limitations of the adenovirus system used for islet 
transfection.  Dividing cells currently do not receive the transgene; use of an AAV system will 
permit tracking of cell replication.   
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 CHAPTER III 
 
FUTURE WORK 
 
 Future work will incorporate measurements made using the constant light emission 
models of islet bioluminescence to correlate photon-counting measurements of islets to the islet 
number surviving post-transplantation.  This will yield insight into the fate and survival rate of 
transplanted islets.  A number of interventions will be introduced to islet transplant recipients; 
their effects can be quantified by bioluminescence measurements. 
 We are also currently working on the development and characterization of two transgenic 
mouse models.  The first expresses the reporter gene luciferase under control of the PDX-1 
promoter, a beta cell specific marker.  The second is also beta-cell specific, expressing luciferase 
under control of the insulin promoter.  These transgenic mouse models will express luciferase 
solely in the beta cells, rather than throughout the islet.  This will allow non-invasive 
measurement of beta cell mass specifically, rather than islet mass as a whole.   
 Results from the rotational experiments will be correlated to measurements of surface 
normals.  Surface normals can be found using a laser range scanner; they are expected to 
correlate to bioluminescence measurements as a function of angle of rotation.  This information 
can be applied to tomographic bioluminescence imaging. 
 Bioluminescence imaging will also be co-registered to other imaging modalities.  Pilot 
studies have shown that the luminescent beads used in this study can be imaged in a phantom in 
an MR scanner.  Co-registration between imaging modalities can combine gene specific 
bioluminescence with the superior spatial resolution offered by MRI.  Integration of the two 
modalities can enhance the potential of in vivo bioluminescence imaging (BLI).   We are also 
developing multi modality probes (rfp-luc-tk) which can be used in confocal microscopy, and 
IBL, as well as PET [38].   
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